

Supporting information for

**Organocatalyzed Nucleophilic Addition of Pyrazoles to 2H-Azirines:
Asymmetric Synthesis of 3,3-Disubstituted Aziridines and Kinetic Resolution
of Racemic 2H-Azirines**

Dong An, Xukai Guan, Rui Guan, Lajiao Jin, Guangliang Zhang, Suoqin Zhang*

College of Chemistry, Jilin University, 2699 Qianjin Street, Changchun 130012, China

Table of Contents


1. General Remarks	S2
2. General procedure and characterization data for racemic 2H-azirine carboxylic esters 2	S2-S4
3. General procedure and characterization data for chiral 2H-azirine carboxylic esters (<i>R</i>)-2	S4-S6
4. General procedure and characterization data for chiral aziridines 3	S6-S12
5. General procedure and characterization data for aziridine (2 <i>S</i> , 3 <i>R</i>)-3n	S12-S13
6. General procedure and characterization data for chiral imidodiphosphoric acids 4	S13
7. General procedure and characterization data for chiral aziridines 6	S14
8. X-Ray Structures of 3e	S14
9. References	S15
10. NMR spectra	S16-S53
11. HPLC spectra of racemic and enantioenriched products	S54-S88

General Remarks: All reagents were used without purification. All solvents were purified and dried according to standard methods. The reaction products were purified by flash column chromatography on 200-300 mesh silica gel. The melting point was recorded on a melting point apparatus (MPA100, Stanford Research Systems, Inc.). Optical rotations were measured with a Jasco-P-2000 digital polarimeter at 20 or 25 °C and concentrations (c) are given in g × (100 mL)⁻¹. ¹H and ¹³C NMR spectra were recorded with Bruker 400 MHz spectrometers (400 MHz for ¹H NMR, 101 MHz for ¹³C NMR); chemical shifts (δ) are given in ppm. High-resolution mass spectral analysis (HRMS) data were measured on a Bruker ApexII mass spectrometer by means of the ESI technique. Analytical HPLC was recorded on a HPLC machine equipped with Elite P1201 series or Ichrom 5100 series quaternary pump with a UV diode array detector. Enantiomeric excess values were measured by analytical HPLC with Daicel ChiralPak AS-H or Daicel Chiralcel OD-H column. 5-aryl-1H-pyrazole-3-carboxylic esters **1** were synthesized according to literature procedures.¹

General procedure and characterization data for racemic 2H-azirine carboxylic esters **2**:

Racemic 2H-azirine carboxylic esters **2** were synthesized according to literature procedures.² Compounds **2a**, **2b**, **2d**, **2i**, **2j**, **2m** and **2o** are known compounds.¹ Compounds **2c**, **2e-2h**, **2k**, **2l** and **2n** were first synthesized in this work and the characterization data was given.

General procedure for aliphatic substituted 2H-azirine carboxylic esters **2a-2i**:




To a solution of NH₂OH HCl (11 mmol, 1.1 equiv.) in 20 mL CH₃OH was added aliphatic substituted β-ketoester (10 mmol, 1.0 equiv.) dropwise and the solution was stirred for 1-2 h. After completion of reaction, the solvent was removed under reduced pressure. 30 mL ethyl acetate and 5 mL water was added and the organic and the aqueous layer were separated. The aqueous layer was extracted twice with ethyl acetate. The combined organic layers were dried over MgSO₄ and concentrated in vacuo to give crude product without purification. (The products ketoximes are unstable and should be used for next step as soon as possible.)

To the ketoxime produced in the previous step, TsCl (12 mmol, 1.2 equiv.) and pyridine (12 mmol, 1.2 equiv.) were added. The solution was stirred for 6 h at 25°C. After the reaction was completed, the solvent was removed in vacuo and the crude material was purified by column chromatography.

To a solution of ketoximetosylate (5 mmol, 1 equiv.) in 10 mL CH₂Cl₂, Et₃N (5.5 mmol, 1.1 equiv.) was added dropwise at 0 °C. After stirring at 0 °C for 15-30 min, the mixture was stirred at 25 °C for 6h. After the reaction was completed, the solvent was removed in vacuo and the crude material was purified by column chromatography.

General procedure for aromatic substituted 2H-azirine carboxylic esters **2j-2o**:




To a solution of NH₂OH HCl (11 mmol, 1.1 equiv.) in 20 mL CH₃OH was added aromatic substituted β-ketoester (10 mmol, 1.0 equiv.) dropwise and the solution was stirred for 4-8 h. After completion of reaction, the solvent was removed under reduced pressure. 30 mL ethyl acetate and 5 mL water was added and the

organic and the aqueous layer were separated. The aqueous layer was extracted twice with ethyl acetate. The combined organic layers were washed with 10 mL saturated Na_2CO_3 and saturated brine (10 mL $\times$ 3), dried over MgSO_4 and concentrated in vacuo to give crude product without purification. (The products ketoximes are unstable and should be used for next step as soon as possible.)


To the ketoxime produced in the previous step, TsCl (6 mmol, 1.2 equiv.) and pyridine (6 mmol, 1.2 equiv.) were added. The solution was stirred for 3 h at 0 °C. After the reaction was completed, the solvent was removed in vacuo and the crude material was purified by column chromatography.

To a solution of ketoximetosylate (5 mmol, 1 equiv.) in 10 mL CH_2Cl_2 , DBU (6.0 mmol, 1.2 equiv.) was added dropwise at 0 °C. After stirring at 0 °C for 15-30 min, the mixture was stirred at 25 °C for 2h. After the reaction was completed, 20 mL ethyl acetate and 5 mL water was added. The aqueous layer was extracted twice with ethyl acetate. The combined organic layers were washed with saturated brine (10 mL $\times$ 3), dried over MgSO_4 and concentrated in vacuo. The crude material was purified by column chromatography.


Characterization data for racemic 2H-azirine carboxylic esters **2**:




Isopropyl 3-methyl-2H-azirine-2-carboxylate ($\pm$)-**2c**: colorless oil, 79% yield (from the corresponding keto ester), ^1H NMR (400 MHz, CDCl_3) δ 5.08-4.99 (m, 1H), 2.53 (s, 3H), 2.41 (s, 1H), 1.24 (s, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.43, 159.10, 68.50, 28.91, 21.73, 21.68, 12.45. HRMS(ESI) m/z calcd for $\text{C}_7\text{H}_{12}\text{NO}_2$ ($[\text{M}+\text{H}]^+$): 142.0868, found: 142.0862.




Methyl 3-propyl-2H-azirine-2-carboxylate ($\pm$)-**2e**: colorless oil, 66% yield (from the corresponding keto ester), ^1H NMR (400 MHz, CDCl_3) δ 3.73 (s, 3H), 2.81 (t, J = 7.2 Hz, 2H), 2.45 (s, 1H), 1.81 (q, J = 7.2 Hz, 2H), 1.07 (t, J = 7.4 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 172.47, 161.77, 51.98, 28.46, 28.35, 17.74, 13.54. HRMS(ESI) m/z calcd for $\text{C}_7\text{H}_{12}\text{NO}_2$ ($[\text{M}+\text{H}]^+$): 142.0868, found: 142.0866.




Methyl 3-pentyl-2H-azirine-2-carboxylate ($\pm$)-**2f**: colorless oil, 67% yield (from the corresponding keto ester), ^1H NMR (300 MHz, CDCl_3) δ 3.72 (s, 3H), 2.82 (t, J = 7.4 Hz, 2H), 2.44 (s, 1H), 1.81-1.72 (m, 2H), 1.48-1.32 (m, 4H), 0.92 (t, J = 7.0 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 172.50, 161.94, 52.02, 31.06, 28.48, 26.59, 23.76, 22.08, 13.72. HRMS(ESI) m/z calcd for $\text{C}_9\text{H}_{16}\text{NO}_2$ ($[\text{M}+\text{H}]^+$): 170.1181, found: 170.1176.




Methyl 3-hexyl-2H-azirine-2-carboxylate ($\pm$)-**2g**: colorless oil, 55% yield (from the corresponding keto ester), ^1H NMR (400 MHz, CDCl_3) δ 3.72 (s, 3H), 2.82 (t, J = 7.3 Hz, 2H), 2.44 (s, 1H), 1.82-1.70 (m, 2H), 1.45-1.40 (m, 2H), 1.39-1.26 (m, 4H), 0.90 (t, J = 6.5 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 172.50, 161.94, 52.03, 31.19, 28.63, 28.49, 26.63, 24.06, 22.31, 13.88. HRMS(ESI) m/z calcd for $\text{C}_{10}\text{H}_{18}\text{NO}_2$ ($[\text{M}+\text{H}]^+$): 184.1338, found: 184.1334.




Methyl 3-isobutyl-2H-azirine-2-carboxylate ($\pm$)-**2h**: colorless oil, 14% yield (from the corresponding keto ester), ^1H NMR (400 MHz, CDCl_3) δ 3.73 (s, 3H), 2.73 (d, J = 6.8 Hz, 2H), 2.42 (s, 1H), 2.23-2.13 (m, 1H), 1.07 (t, J = 9.0 Hz, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 172.53, 161.24, 52.05, 35.31, 28.20, 25.32, 22.34. HRMS(ESI) m/z calcd for $\text{C}_8\text{H}_{14}\text{NO}_2$ ($[\text{M}+\text{H}]^+$): 156.1025, found: 156.1028.



Methyl 3-(4-bromophenyl)-2H-azirine-2-carboxylate (±)-**2k**: white solid, 17% yield, (from the corresponding keto ester), m.p. 68.2-68.7 °C, ¹H NMR (400 MHz, CDCl₃) δ 7.87-7.68 (m, 4H), 3.75 (s, 3H), 2.87 (s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 171.64, 157.99, 132.72, 131.54, 128.97, 121.06, 52.29, 29.54. HRMS(ESI) *m/z* calcd for C₁₀H₉BrNO₂ ([M+H]⁺): 253.9811, found: 253.9800.




Methyl 3-(4-chlorophenyl)-2H-azirine-2-carboxylate (±)-**2l**: white solid, 11% yield (from the corresponding keto ester), m.p. 63.4-64.2 °C, ¹H NMR (400 MHz, CDCl₃) δ 7.84 (d, *J* = 7.0 Hz, 2H), 7.57 (d, *J* = 7.0 Hz, 2H), 3.75 (s, 3H), 2.87 (s, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 171.70, 157.82, 140.37, 131.51, 129.77, 120.66, 52.31, 29.57. HRMS(ESI) *m/z* calcd for C₁₀H₉ClNO₂ ([M+H]⁺): 210.0316, found: 210.0309.



Methyl 3-(4-(trifluoromethyl)phenyl)-2H-azirine-2-carboxylate (±)-**2n**: colorless oil, 26% yield (from the corresponding keto ester), ¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, *J* = 8.0 Hz, 2H), 7.86 (d, *J* = 8.0 Hz, 2H), 3.76 (s, 3H), 2.94 (s, 1H). ¹³C NMR (75 MHz, CDCl₃) δ 171.36, 158.53, 135.25 (q, *J* = 32.7 Hz), 130.57, 126.30 (q, *J* = 3.7 Hz), 125.71, 123.25 (q, *J* = 271.3 Hz), 52.29, 29.91. HRMS(ESI) *m/z* calcd for C₁₁H₉F₃NO₂ ([M+H]⁺): 244.0580, found: 244.0567.

General procedure and characterization data for chiral 2H-azirine carboxylic esters (*R*)-2:

General procedure for chiral 2H-azirine carboxylic esters (*R*)-2:




For **2a-d**: A solution of ethyl 3-(4-bromophenyl)-1H-pyrazole-5-carboxylate **1a** (0.1 mmol) and catalyst **4e** (10 mol %, 0.01 mmol) in 0.9 mL cyclohexane and 0.1 mL toluene was stirred at -20 °C for 10 min, then racemic 2H-azirine carboxylic esters **2** (0.18 mmol) was added. The reaction mixture was stirred at -20 °C for 3 d. After removal of the solvent, the residue was purified by flash column chromatography to afford the pure products.


For **2e**, **2g** and **2i**: A solution of ethyl 3-(4-bromophenyl)-1H-pyrazole-5-carboxylate **1a** (0.1 mmol) and catalyst **4e** (10 mol %, 0.01 mmol) in 0.9 mL cyclohexane and 0.1 mL toluene was stirred at 0 °C for 10 min, then racemic 2H-azirine carboxylic esters **2** (0.18 mmol) was added. The reaction mixture was stirred at 0 °C for 3 d. After removal of the solvent, the residue was purified by flash column chromatography to afford the pure products.

For **2k**, **2l** and **2n**: A solution of ethyl 3-(4-bromophenyl)-1H-pyrazole-5-carboxylate **1a** (0.1 mmol) and catalyst **4e** (10 mol %, 0.01 mmol) in 0.9 mL cyclohexane and 0.1 mL toluene was stirred at 25 °C for 10 min, then racemic 2H-azirine carboxylic esters **2** (0.18 mmol) was added. The reaction mixture was stirred at 25 °C for 6 d. After removal of the solvent, the residue was purified by flash column chromatography to afford the pure products.


Characterization data for chiral 2H-azirine carboxylic esters (*R*)-2:




(*R*)-ethyl 3-methyl-2H-azirine-2-carboxylate (*R*)-**2a**: colorless oil, 49% yield, 98% ee [Daicel Chiralcel OD-H column, *n*-hexane / *i*-PrOH = 98 : 2, 1.0 ml/min, λ = 210 nm, *t* (minor) = 8.55 min, *t* (major) = 12.77 min]; $[\alpha]_D^{25}$ = -223.2 (*c* = 0.112, EtOAc). ^1H NMR (300 MHz, CDCl_3) δ 4.25-4.12 (m, 2H), 2.53 (s, 3H), 2.44 (s, 1H), 1.27 (t, *J* = 7.1 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.92, 159.07, 61.02, 28.71, 14.12, 12.48. HRMS(ESI) *m/z* calcd for $\text{C}_6\text{H}_{10}\text{NO}_2$ ($[\text{M}+\text{H}]^+$): 128.0712, found: 128.0716.




(*R*)-methyl 3-methyl-2H-azirine-2-carboxylate (*R*)-**2b**: colorless oil, 48% yield, 99% ee [Daicel Chiralcel OD-H column, *n*-hexane / *i*-PrOH = 99 : 1, 1.0 ml/min, λ = 210 nm, *t* (minor) = 12.39 min, *t* (major) = 18.23 min]; $[\alpha]_D^{25}$ = -140.5 (*c* = 0.195, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 3.73 (s, 3H), 2.54 (s, 3H), 2.46 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 172.25, 158.96, 51.97, 28.46, 12.38. HRMS(ESI) *m/z* calcd for $\text{C}_5\text{H}_8\text{NO}_2$ ($[\text{M}+\text{H}]^+$): 114.0555, found: 114.0563.




(*R*)-isopropyl 3-methyl-2H-azirine-2-carboxylate (*R*)-**2c**: colorless oil, 48% yield, 99% ee [Daicel Chiralcel OD-H column, *n*-hexane / *i*-PrOH = 99 : 1, 1.0 ml/min, λ = 210 nm, *t* (minor) = 8.51 min, *t* (major) = 10.74 min]; $[\alpha]_D^{25}$ = -161.5 (*c* = 0.112, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 5.16-4.97 (m, 1H), 2.52 (s, 3H), 2.41 (s, 1H), 1.25 (d, *J* = 6.2 Hz, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.57, 159.24, 68.65, 28.94, 21.75, 12.46. HRMS(ESI) *m/z* calcd for $\text{C}_7\text{H}_{12}\text{NO}_2$ ($[\text{M}+\text{H}]^+$): 142.0868, found: 142.0856.




(*R*)-benzyl 3-methyl-2H-azirine-2-carboxylate (*R*)-**2d**: colorless oil, 49% yield, 99% ee [Daicel Chiralcel OD-H column, *n*-hexane / *i*-PrOH = 98 : 2, 0.5 ml/min, λ = 225 nm, *t* (minor) = 15.92 min, *t* (major) = 25.96 min]; $[\alpha]_D^{25}$ = -129.8 (*c* = 0.168, EtOAc). ^1H NMR (300 MHz, CDCl_3) δ 7.45-7.29 (m, 5H), 5.19 (d, *J* = 12.3 Hz, 1H), 5.14 (d, *J* = 12.3 Hz, 1H), 2.52 (s, 3H), 2.49 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.77, 158.89, 135.49, 128.46, 128.22, 128.12, 66.71, 28.68, 12.44. HRMS(ESI) *m/z* calcd for $\text{C}_{11}\text{H}_{12}\text{NO}_2$ ($[\text{M}+\text{H}]^+$): 190.0868, found: 190.0864.




(*R*)-methyl 3-propyl-2H-azirine-2-carboxylate (*R*)-**2e**: colorless oil, 48% yield, 97% ee [Daicel Chiralcel OD-H column, *n*-hexane / *i*-PrOH = 99 : 1, 1.0 ml/min, λ = 210 nm, *t* (minor) = 9.43 min, *t* (major) = 20.27 min]; $[\alpha]_D^{25}$ = -195.0 (*c* = 0.121, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 3.73 (s, 3H), 2.81 (t, *J* = 7.2 Hz, 2H), 2.45 (s, 1H), 1.81 (q, *J* = 7.2 Hz, 2H), 1.07 (t, *J* = 7.4 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 172.47, 161.77, 51.98, 28.46, 28.35, 17.74, 13.54. HRMS(ESI) *m/z* calcd for $\text{C}_7\text{H}_{12}\text{NO}_2$ ($[\text{M}+\text{H}]^+$): 142.0868, found: 142.0866.




(*R*)-methyl 3-hexyl-2H-azirine-2-carboxylate (*R*)-**2g**: colorless oil, 49% yield, 99% ee [Daicel Chiralcel OD-H column, *n*-hexane / *i*-PrOH = 98 : 2, 1.0 ml/min, λ = 210 nm, *t* (minor) = 6.29 min, *t* (major) = 9.75 min]; $[\alpha]_D^{25}$ = -216.1 (*c* = 0.161, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 3.72 (s, 3H), 2.82 (t, *J* = 7.3 Hz, 2H), 2.44 (s, 1H), 1.82-1.70 (m, 2H), 1.45-1.40 (m, 2H), 1.39-1.26 (m, 4H), 0.90 (t, *J* = 6.5 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 172.50, 161.94, 52.03, 31.19, 28.63, 28.49, 26.63, 24.06, 22.31, 13.88. HRMS(ESI) *m/z* calcd for $\text{C}_{10}\text{H}_{18}\text{NO}_2$ ($[\text{M}+\text{H}]^+$): 184.1338, found: 184.1334.




(*R*)-ethyl 3-benzyl-2H-azirine-2-carboxylate (*R*)-**2i**: colorless oil, 45% yield, 94% ee [Daicel Chiralcel OD-H column, *n*-hexane / *i*-PrOH = 98 : 2, 1.0 ml/min, λ = 225 nm, *t* (minor) = 16.40 min, *t* (major) = 24.27 min]; $[\alpha]_D^{25}$ = -275.2 (*c* = 0.164, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.40-7.28 (m, 5H), 4.25-4.09 (m, 4H), 2.51 (s, 1H), 1.21 (t, *J* = 7.1 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.65, 161.29, 131.57, 128.89, 128.70, 127.65, 61.04, 32.89, 29.15, 14.05. HRMS(ESI) *m/z* calcd for $\text{C}_{12}\text{H}_{14}\text{NO}_2$ ($[\text{M}+\text{H}]^+$): 204.1025, found: 204.1018.



(*R*)-methyl 3-(4-bromophenyl)-2H-azirine-2-carboxylate (*R*)-**2k**: white solid, 48% yield, 97% ee [Daicel Chiralcel OD-H column, *n*-hexane / *i*-PrOH = 95 : 5, 1.0 ml/min, λ = 254 nm, *t* (minor) = 10.27 min, *t* (major) = 15.90 min]; m.p. 68.2-68.7 °C, $[\alpha]_D^{25}$ = -377.3 (*c* = 0.220, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.87-7.68 (m, 4H), 3.75 (s, 3H), 2.87 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.64, 157.99, 132.72, 131.54, 128.97, 121.06, 52.29, 29.54. HRMS(ESI) *m/z* calcd for $\text{C}_{10}\text{H}_9\text{BrNO}_2$ ($[\text{M}+\text{H}]^+$): 253.9811, found: 253.9800.




(*R*)-methyl 3-(4-chlorophenyl)-2H-azirine-2-carboxylate (*R*)-**2l**: white solid, 49% yield, 96% ee [Daicel Chiralcel OD-H column, *n*-hexane / *i*-PrOH = 95 : 5, 1.0 ml/min, λ = 254 nm, *t* (minor) = 9.32 min, *t* (major) = 14.10 min]; m.p. 63.4-64.2 °C, $[\alpha]_D^{25}$ = -602.2 (*c* = 0.184, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.84 (d, *J* = 7.0 Hz, 2H), 7.57 (d, *J* = 7.0 Hz, 2H), 3.75 (s, 3H), 2.87 (s, 1H). ^{13}C NMR (101 MHz, CDCl_3) δ 171.70, 157.82, 140.37, 131.51, 129.77, 120.66, 52.31, 29.57. HRMS(ESI) *m/z* calcd for $\text{C}_{10}\text{H}_9\text{ClNO}_2$ ($[\text{M}+\text{H}]^+$): 210.0316, found: 210.0309.



(*R*)-methyl 3-(4-(trifluoromethyl)phenyl)-2H-azirine-2-carboxylate (*R*)-**2n**: colorless oil, 46% yield, 98% ee [Daicel Chiralcel OD-H column, *n*-hexane / *i*-PrOH = 97 : 3, 1.0 ml/min, λ = 254 nm, *t* (minor) = 9.49 min, *t* (major) = 17.24 min]; $[\alpha]_D^{25}$ = -518.2 (*c* = 0.203, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 8.03 (d, *J* = 8.0 Hz, 2H), 7.86 (d, *J* = 8.0 Hz, 2H), 3.76 (s, 3H), 2.94 (s, 1H). ^{13}C NMR (75 MHz, CDCl_3) δ 171.36, 158.53, 135.25 (q, *J* = 32.7 Hz), 130.57, 126.30 (q, *J* = 3.7 Hz), 125.71, 123.25 (q, *J* = 271.3 Hz), 52.29, 29.91. HRMS(ESI) *m/z* calcd for $\text{C}_{11}\text{H}_9\text{F}_3\text{NO}_2$ ($[\text{M}+\text{H}]^+$): 244.0580, found: 244.0567.

General procedure and characterization data for chiral arylpyrazole substituted aziridines **3**:


General procedure for chiral arylpyrazole substituted aziridines **3**:




For **3a-3i** and **3p-3w**: A solution of 5-aryl-1H-pyrazole-3-carboxylic esters **1** (0.1 mmol) and catalyst **4e** (10 mol %, 0.01 mmol) in 0.9 mL cyclohexane and 0.1 mL toluene was stirred at -20 °C for 10 min, then racemic 2H-azirine carboxylic esters **2** (0.3 mmol) was added. The reaction mixture was stirred at -20 °C until the reaction was completed. After removal of the solvent, the residue was purified by flash column chromatography to afford the pure products.

For **3k-3o**: A solution of 5-aryl-1H-pyrazole-3-carboxylic esters **1** (0.1 mmol) and catalyst **4e** (10 mol %, 0.01 mmol) in 0.9 mL cyclohexane and 0.1 mL toluene was stirred at 25 °C for 10 min, then racemic 2H-azirine carboxylic esters **2** (0.3 mmol) was added. The reaction mixture was stirred at 25 °C until the reaction was completed. After removal of the solvent, the residue was purified by flash column chromatography to afford the pure products.


Characterization data for chiral arylpyrazole substituted aziridines **3**:




Ethyl 3-(4-bromophenyl)-1-((2R,3S)-3-(ethoxycarbonyl)-2-methylaziridin-2-yl)-1H-pyrazole-5-carboxylate **3a**: colourless oil, 97% yield, 99.9% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, *t* (major) = 7.73 min, *t* (minor) = 15.77 min]; $[\alpha]_D^{25}$ = +257.4 (*c* = 0.408, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.69 (d, *J* = 8.5 Hz, 2H), 7.53 (d, *J* = 8.4 Hz, 2H), 7.09 (s, 1H), 4.48-4.28 (m, 4H), 3.16 (s, 1H), 2.04 (brs, 1H), 1.93 (s, 3H), 1.45-1.36 (m, 6H). ^{13}C NMR (101 MHz, CDCl_3) δ 169.35, 158.67, 149.29, 134.20, 131.74, 131.16, 127.33, 122.25, 108.68, 62.21, 61.36, 58.42, 42.17, 18.48, 14.20. HRMS(ESI) *m/z* calcd for $\text{C}_{18}\text{H}_{21}\text{BrN}_3\text{O}_4$ ($[\text{M}+\text{H}]^+$): 422.0715, found: 422.0715.



Ethyl 3-(4-bromophenyl)-1-((2R,3S)-3-(methoxycarbonyl)-2-methylaziridin-2-yl)-1H-pyrazole-5-carboxylate **3b**: colourless oil, 96% yield, 99.9% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, *t* (major) = 9.20 min, *t* (minor) = 18.72 min]; $[\alpha]_D^{25}$ = +226.1 (*c* = 0.452, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.69 (d, *J* = 8.1 Hz, 2H), 7.52 (d, *J* = 8.3 Hz, 2H), 7.09 (s, 1H), 4.48-4.33 (m, 2H), 3.90 (s, 3H), 3.18 (s, 1H), 2.04 (brs, 1H), 1.93 (s, 3H), 1.41 (t, *J* = 7.1 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 169.70, 158.63, 149.27, 134.13, 131.71, 131.06, 127.28, 122.23, 108.72, 61.36, 58.43, 52.89, 42.01, 18.51, 14.16. HRMS(ESI) *m/z* calcd for $\text{C}_{17}\text{H}_{19}\text{BrN}_3\text{O}_4$ ($[\text{M}+\text{H}]^+$): 408.0559, found: 408.0559.




Ethyl 3-(4-bromophenyl)-1-((2R,3S)-3-(isopropoxycarbonyl)-2-methylaziridin-2-yl)-1H-pyrazole-5-carboxylate **3c**: colourless oil, 98% yield, 99.9% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, *t* (major) = 7.84 min, *t* (minor) = 14.96 min]; $[\alpha]_D^{25}$ = +222.1 (*c* = 0.426, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.70 (d, *J* = 8.2 Hz, 2H), 7.53 (d, *J* = 8.2 Hz, 2H), 7.08 (s, 1H), 5.23-5.14 (m, 1H), 4.49-4.31 (m, 2H), 3.12 (s, 1H), 2.01 (brs, 1H), 1.93 (s, 3H), 1.46-1.30 (m, 9H). ^{13}C NMR (101 MHz, CDCl_3) δ 168.71, 158.62, 149.21, 134.21, 131.73, 131.16, 127.33, 122.21, 108.62, 70.04, 61.29, 58.29, 42.35, 21.86, 21.77, 18.43, 14.22. HRMS(ESI) *m/z* calcd for $\text{C}_{19}\text{H}_{23}\text{BrN}_3\text{O}_4$ ($[\text{M}+\text{H}]^+$): 436.0872, found: 436.0869.




Ethyl 1-((2R,3S)-3-((benzyloxy)carbonyl)-2-methylaziridin-2-yl)-3-(4-bromophenyl)-1H-pyrazole-5-carboxylate **3d**: colourless oil, 98% yield, 99.9% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, *t* (major) = 13.13 min, *t* (minor) = 26.15 min]; $[\alpha]_D^{25}$ = +246.5 (*c* = 0.473, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.68 (d, *J* = 7.8 Hz, 2H), 7.52 (d, *J* = 8.1 Hz, 2H), 7.49-7.30 (m, 5H), 7.08 (s, 1H), 5.33 (s, 2H), 4.40-4.35 (m, 2H), 3.21 (s, 1H), 2.04 (brs, 1H), 1.92 (s, 3H), 1.44-1.32 (t, *J* = 6.0 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 169.11, 158.61,


149.29, 135.07, 134.10, 131.72, 131.00, 128.60, 128.52, 128.34, 127.30, 122.25, 108.69, 67.70, 61.34, 58.48, 42.17, 18.54, 14.18. HRMS(ESI) m/z calcd for $C_{23}H_{23}BrN_3O_4$ ($[M+H]^+$): 484.0872, found: 484.0861.




Ethyl 3-(4-bromophenyl)-1-((2R,3S)-3-(methoxycarbonyl)-2-propylaziridin-2-yl)-1H-pyrazole-5-carboxylate **3e**: white solid, 96% yield, 99.6% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, t (major) = 6.55 min, t (minor) = 18.88 min]; m.p. 130.6-131.2 °C, $[\alpha]_D^{25}$ = +252.4 (c = 0.416, EtOAc). 1H NMR (400 MHz, $CDCl_3$) δ 7.70 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 8.4 Hz, 2H), 7.12 (s, 1H), 4.40 (q, J = 6.0 Hz, 2H), 3.89 (s, 3H), 3.25 (s, 1H), 2.37 (s, 1H), 2.04-1.95 (m, 2H), 1.41 (t, J = 7.1 Hz, 3H), 1.26-1.17 (m, 2H), 0.86 (t, J = 7.4 Hz, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 169.84, 158.67, 148.79, 134.47, 131.72, 131.20, 127.32, 122.19, 109.12, 61.50, 61.34, 52.88, 41.89, 33.87, 18.71, 14.19, 13.49. HRMS(ESI) m/z calcd for $C_{19}H_{23}BrN_3O_4$ ($[M+H]^+$): 436.0872, found: 436.0870.




Ethyl 3-(4-bromophenyl)-1-((2R,3S)-3-(methoxycarbonyl)-2-pentylaziridin-2-yl)-1H-pyrazole-5-carboxylate **3f**: white solid, 92% yield, 99.4% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, t (major) = 5.41 min, t (minor) = 12.31 min]; m.p. 100.3-101.1 °C, $[\alpha]_D^{25}$ = +304.3 (c = 0.370, EtOAc). 1H NMR (400 MHz, $CDCl_3$) δ 7.70 (d, J = 8.3 Hz, 2H), 7.53 (d, J = 8.3 Hz, 2H), 7.12 (s, 1H), 4.40 (q, J = 7.0 Hz, 2H), 3.89 (s, 3H), 3.25 (s, 1H), 2.37 (s, 1H), 2.10-1.92 (m, 2H), 1.41 (t, J = 7.1 Hz, 3H), 1.29-1.11 (m, 6H), 0.80 (t, J = 6.4 Hz, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 169.77, 158.67, 148.78, 134.45, 131.71, 131.20, 127.31, 122.18, 109.14, 61.64, 61.33, 52.86, 41.92, 31.87, 31.04, 24.90, 22.28, 14.19, 13.81. HRMS(ESI) m/z calcd for $C_{19}H_{23}BrN_3O_4$ ($[M+H]^+$): 464.1179, found: 464.1180.




Ethyl 3-(4-bromophenyl)-1-((2R,3S)-2-hexyl-3-(methoxycarbonyl)aziridin-2-yl)-1H-pyrazole-5-carboxylate **3g**: white solid, 86% yield, 99.9% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, t (major) = 4.99 min, t (minor) = 9.88 min]; m.p. 97.2-97.7 °C, $[\alpha]_D^{25}$ = +313.1 (c = 0.411, EtOAc). 1H NMR (400 MHz, $CDCl_3$) δ 7.70 (d, J = 7.5 Hz, 2H), 7.53 (d, J = 7.9 Hz, 2H), 7.13 (s, 1H), 4.40 (q, J = 6.0 Hz, 2H), 3.89 (s, 3H), 3.25 (s, 1H), 2.38 (brs, 1H), 2.02 (t, J = 6.0 Hz, 2H), 1.41 (t, J = 5.6 Hz, 3H), 1.29-1.09 (m, 8H), 0.82 (t, J = 5.7 Hz, 3H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 169.82, 158.68, 148.78, 134.45, 131.71, 131.22, 127.31, 122.20, 109.14, 61.64, 61.33, 52.91, 41.94, 31.94, 31.45, 28.56, 25.32, 22.40, 14.19, 13.92. HRMS(ESI) m/z calcd for $C_{22}H_{29}BrN_3O_4$ ($[M+H]^+$): 478.1336, found: 478.1337.




Ethyl 3-(4-bromophenyl)-1-((2R,3S)-2-isobutyl-3-(methoxycarbonyl)aziridin-2-yl)-1H-pyrazole-5-carboxylate **3h**: white solid, 93% yield, 99.3% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, t (major) = 5.38 min, t (minor) = 11.07 min]; m.p. 123.2-123.8 °C, $[\alpha]_D^{25}$ = +358.9 (c = 0.418, EtOAc). 1H NMR (400 MHz, $CDCl_3$) δ 7.69 (d, J = 7.8 Hz, 2H), 7.52 (d, J = 7.5 Hz, 2H), 7.12 (s, 1H), 4.42-4.32 (m, 2H), 3.88 (s, 3H), 3.29 (s, 1H), 2.43 (brs, 1H), 1.93-1.73 (m, 1H), 1.41 (t, J = 6.8 Hz, 3H), 1.35-1.18 (m, 2H), 0.89 (d, J = 6.8 Hz, 6H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 169.96, 158.65, 148.53, 134.49, 131.72, 131.23, 127.24, 122.16, 109.12, 61.31, 60.87, 52.85, 41.72, 39.65, 25.34, 22.86, 21.76, 14.19. HRMS(ESI) m/z calcd for $C_{20}H_{25}BrN_3O_4$ ($[M+H]^+$): 450.1028, found: 450.1029.




Ethyl 3-(4-bromophenyl)-1-((2R,3S)-3-(ethoxycarbonyl)-2-phenethylaziridin-2-yl)-1H-pyrazole-5-carboxylate **3i**: white solid, 91% yield, 97% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, *t* (major) = 8.35 min, *t* (minor) = 21.40 min]; m.p. 84.5-85.2 °C, $[\alpha]_D^{25}$ = +219.5 (*c* = 0.307, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.53 (d, *J* = 8.4 Hz, 2H), 7.48 (d, *J* = 8.4 Hz, 2H), 7.18-7.11 (m, 3H), 7.05 (s, 1H), 6.92-6.84 (m, 2H), 4.43-4.29 (m, 4H), 3.71 (d, *J* = 14.3 Hz, 1H), 3.39 (d, *J* = 14.8 Hz, 1H), 3.33 (s, 1H), 2.28 (brs, 1H), 1.40 (t, *J* = 7.6 Hz, 3H), 1.38 (t, *J* = 7.6 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 169.37, 158.63, 148.87, 135.22, 134.76, 131.63, 131.14, 129.35, 128.07, 127.39, 126.87, 122.16, 109.19, 62.20, 61.59, 61.29, 42.44, 38.20, 14.21. HRMS(ESI) *m/z* calcd for $\text{C}_{24}\text{H}_{25}\text{BrN}_3\text{O}_4$ ($[\text{M}+\text{H}]^+$): 498.1023, found: 498.1026.




Ethyl 3-(4-bromophenyl)-1-((2R,3S)-3-(ethoxycarbonyl)-2-phenylaziridin-2-yl)-1H-pyrazole-5-carboxylate **3j**: white solid, 89% yield, 98% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, *t* (major) = 13.76 min, *t* (minor) = 21.66 min]; m.p. 127.0-127.8 °C, $[\alpha]_D^{25}$ = +507.1 (*c* = 0.435, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.76 (d, *J* = 8.1 Hz, 2H), 7.62-7.52 (m, 4H), 7.34-7.26 (m, 3H), 7.09 (s, 1H), 4.32 (q, *J* = 6.9 Hz, 2H), 4.06 (q, *J* = 6.9 Hz, 2H), 3.77 (s, 1H), 2.99 (brs, 1H), 1.34 (t, *J* = 7.1 Hz, 3H), 1.08 (t, *J* = 7.0 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 167.58, 158.34, 149.31, 134.87, 133.70, 131.75, 131.17, 128.81, 127.89, 127.79, 127.39, 122.30, 109.37, 61.85, 61.23, 43.70, 14.17, 13.89. HRMS(ESI) *m/z* calcd for $\text{C}_{23}\text{H}_{23}\text{BrN}_3\text{O}_4$ ($[\text{M}+\text{H}]^+$): 484.0866, found: 484.0857.




Ethyl 3-(4-bromophenyl)-1-((2R,3S)-2-(4-bromophenyl)-3-(methoxycarbonyl)aziridin-2-yl)-1H-pyrazole-5-carboxylate **3k**: white solid, 91% yield, 99.7% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, *t* (major) = 13.05 min, *t* (minor) = 22.37 min]; m.p. 151.2-151.8 °C, $[\alpha]_D^{25}$ = +444.4 (*c* = 0.496, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.74 (d, *J* = 6.8 Hz, 2H), 7.55 (d, *J* = 7.9 Hz, 2H), 7.43 (s, 4H), 7.09 (s, 1H), 4.38-4.24 (m, 2H), 3.80 (s, 1H), 3.66 (s, 3H), 2.92 (brs, 1H), 1.33 (t, *J* = 7.2 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 168.05, 158.29, 149.60, 134.81, 132.79, 131.80, 131.17, 130.93, 129.46, 127.37, 123.19, 122.48, 109.44, 61.38, 52.86, 43.60, 14.17. HRMS(ESI) *m/z* calcd for $\text{C}_{22}\text{H}_{20}\text{Br}_2\text{N}_3\text{O}_4$ ($[\text{M}+\text{H}]^+$): 547.9815, found: 547.9820.




Ethyl 3-(4-bromophenyl)-1-((2R,3S)-2-(4-chlorophenyl)-3-(methoxycarbonyl)aziridin-2-yl)-1H-pyrazole-5-carboxylate **3l**: white solid, 93% yield, 99.9% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, *t* (major) = 7.59 min, *t* (minor) = 12.92 min]; m.p. 148.2-148.7 °C, $[\alpha]_D^{25}$ = +592.3 (*c* = 0.468, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.74 (d, *J* = 8.0 Hz, 2H), 7.55 (d, *J* = 8.0 Hz, 2H), 7.50 (d, *J* = 8.1 Hz, 2H), 7.27 (d, *J* = 8.1 Hz, 2H), 7.10 (s, 1H), 4.32 (q, *J* = 7.2 Hz, 2H), 3.80 (s, 1H), 3.66 (s, 3H), 2.05 (brs, 1H), 1.34 (t, *J* = 7.0 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 168.05, 158.33, 149.61, 134.89, 132.28, 131.83, 130.94, 129.18, 128.25, 127.37, 122.47, 109.44, 99.94, 61.38, 52.85, 43.63, 14.16. HRMS(ESI) *m/z* calcd for $\text{C}_{22}\text{H}_{20}\text{BrClN}_3\text{O}_4$ ($[\text{M}+\text{H}]^+$): 504.0320, found: 504.0321.




Ethyl 3-(4-bromophenyl)-1-((2R,3S)-3-(methoxycarbonyl)-2-(p-tolyl)aziridin-2-yl)-1H-pyrazole-5-carboxylate **3m**: white solid, 74% yield, 99.5% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 95 : 5, 1.0 ml/min, λ = 254 nm, *t* (major) = 17.58 min, *t* (minor) = 29.89 min]; m.p. 134.5-135.2 °C, $[\alpha]_D^{25}$ = +403.9 (*c* = 0.359, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.74 (d, *J* = 7.6 Hz, 2H), 7.54 (d, *J* = 8.0 Hz, 2H), 7.44 (d, *J* = 7.1 Hz, 2H), 7.09 (d, *J* = 7.1 Hz, 2H), 7.08 (s, 1H) 4.32 (q, *J* = 6.5 Hz, 2H), 3.75 (s, 1H), 3.65 (s, 3H), 2.95 (brs, 1H), 2.29 (s, 3H), 1.34 (t, *J* = 7.0 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 168.43, 158.37, 149.32, 138.78, 134.76, 131.75, 131.19, 130.70, 128.70, 127.56, 127.39, 122.29, 109.35, 61.25, 52.78, 43.59, 21.21, 14.19. HRMS(ESI) *m/z* calcd for $\text{C}_{23}\text{H}_{23}\text{BrN}_3\text{O}_4$ ($[\text{M}+\text{H}]^+$): 484.0872, found: 484.0867.




Ethyl 3-(4-bromophenyl)-1-((2R,3S)-3-(methoxycarbonyl)-2-(4-(trifluoromethyl)phenyl)aziridin-2-yl)-1H-pyrazole-5-carboxylate **3n**: white solid, 90% yield, 99.9% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, *t* (major) = 8.68 min, *t* (minor) = 13.26 min]; m.p. 138.5-139.2 °C, $[\alpha]_D^{25}$ = +576.4 (*c* = 0.483, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.75 (d, *J* = 7.8 Hz, 2H), 7.69 (d, *J* = 7.4 Hz, 2H), 7.56 (d, *J* = 7.7 Hz, 4H), 7.11 (s, 1H), 4.31 (q, *J* = 6.4 Hz, 2H), 3.84 (s, 1H), 3.65 (s, 3H), 3.00 (brs, 1H), 1.34 (t, *J* = 6.8 Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 167.73, 158.22, 149.78, 137.65, 135.03, 131.79, 130.87, 130.82 (q, *J* = 32.3 Hz), 128.25, 127.35, 125.12, 124.87 (d, *J* = 3.5 Hz), 123.78 (q, *J* = 271.1 Hz), 109.45, 61.37, 52.64, 43.80, 14.04. HRMS(ESI) *m/z* calcd for $\text{C}_{23}\text{H}_{20}\text{BrF}_3\text{N}_3\text{O}_4$ ($[\text{M}+\text{H}]^+$): 538.0584, found: 538.0581.




Ethyl 3-(4-bromophenyl)-1-((2R,3S)-2-(3-chlorophenyl)-3-(methoxycarbonyl)aziridin-2-yl)-1H-pyrazole-5-carboxylate **3o**: white solid, 86% yield, 99% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 95 : 5, 1.0 ml/min, λ = 254 nm, *t* (major) = 18.37 min, *t* (minor) = 39.18 min]; m.p. 143.3-144.0 °C, $[\alpha]_D^{25}$ = +501.4 (*c* = 0.434, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.75 (d, *J* = 8.0 Hz, 2H), 7.60-7.55 (m, 3H), 7.47 (d, *J* = 6.2 Hz, 1H), 7.30-7.19 (m, 2H), 7.11 (s, 1H), 4.33 (q, *J* = 6.8 Hz, 2H), 3.79 (s, 1H), 3.67 (s, 3H), 2.90 (brs, 1H), 1.35 (t, *J* = 7.0 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 167.93, 158.30, 149.69, 135.68, 134.87, 133.92, 131.81, 130.92, 129.24, 129.15, 128.03, 127.40, 125.99, 122.50, 109.52, 61.44, 52.85, 43.70, 14.17. HRMS(ESI) *m/z* calcd for $\text{C}_{22}\text{H}_{20}\text{BrClN}_3\text{O}_4$ ($[\text{M}+\text{H}]^+$): 504.0326, found: 504.0321.




Ethyl 3-(4-chlorophenyl)-1-((2R,3S)-3-(methoxycarbonyl)-2-methylaziridin-2-yl)-1H-pyrazole-5-carboxylate **3p**: white solid, 98% yield, 99.9% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 95 : 5, 1.0 ml/min, λ = 254 nm, *t* (major) = 11.93 min, *t* (minor) = 27.15 min]; m.p. 93.3-94.0 °C, $[\alpha]_D^{25}$ = +234.2 (*c* = 0.357, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.75 (d, *J* = 8.5 Hz, 2H), 7.37 (d, *J* = 8.4 Hz, 2H), 7.09 (s, 1H), 4.52-4.30 (m, 2H), 3.90 (s, 3H), 3.19 (s, 1H), 2.04 (brs, 1H), 1.93 (s, 3H), 1.41 (t, *J* = 7.1 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 169.85, 158.68, 149.30, 134.14, 134.07, 130.64, 128.80, 127.03, 108.75, 61.38, 58.45, 52.93, 42.05, 18.55, 14.19. HRMS(ESI) *m/z* calcd for $\text{C}_{17}\text{H}_{19}\text{ClN}_3\text{O}_4$ ($[\text{M}+\text{H}]^+$): 364.1064, found: 364.1065.




Isopropyl 3-(4-chlorophenyl)-1-((2R,3S)-3-(methoxycarbonyl)-2-methylaziridin-2-yl)-1H-pyrazole-5-carboxylate **3q**: white solid, 97% yield, 99.9% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, *t* (major) = 6.63 min, *t* (minor) = 10.25 min]; m.p. 113.3-114.1 °C, $[\alpha]_{\text{D}}^{25}$ = +240.0 (*c* = 0.365, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.75 (d, *J* = 8.5 Hz, 2H), 7.37 (d, *J* = 8.5 Hz, 2H), 7.06 (s, 1H), 5.32-5.23 (m, 1H), 3.90 (s, 3H), 3.19 (s, 1H), 2.04 (brs, 1H), 1.94 (s, 3H), 1.40 (d, *J* = 4.0 Hz, 3H), 1.39 (d, *J* = 4.0 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 169.84, 158.24, 149.18, 134.58, 134.01, 130.70, 128.78, 127.02, 108.62, 69.19, 58.47, 52.91, 41.99, 21.81, 18.55. HRMS(ESI) *m/z* calcd for $\text{C}_{18}\text{H}_{21}\text{ClN}_3\text{O}_4$ ($[\text{M}+\text{H}]^+$): 378.1221, found: 378.1218.




Ethyl 3-(3-chlorophenyl)-1-((2R,3S)-3-(methoxycarbonyl)-2-methylaziridin-2-yl)-1H-pyrazole-5-carboxylate **3r**: white solid, 97% yield, 99.9% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, *t* (major) = 7.87 min, *t* (minor) = 16.21 min]; m.p. 87.1-87.8 °C, $[\alpha]_{\text{D}}^{25}$ = +252.1 (*c* = 0.357, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.83 (s, 1H), 7.69 (d, *J* = 7.2 Hz, 1H), 7.37-7.28 (m, 2H), 7.11 (s, 1H), 4.51-4.32 (m, 2H), 3.90 (s, 3H), 3.20 (s, 1H), 2.05 (brs, 1H), 1.93 (s, 3H), 1.42 (t, *J* = 6.6 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 169.81, 158.62, 149.01, 134.63, 134.16, 133.89, 129.85, 128.20, 125.79, 123.83, 108.89, 61.37, 58.48, 52.90, 42.00, 18.50, 14.16. HRMS(ESI) *m/z* calcd for $\text{C}_{17}\text{H}_{19}\text{ClN}_3\text{O}_4$ ($[\text{M}+\text{H}]^+$): 364.1064, found: 364.1056.



Ethyl 3-(2-chlorophenyl)-1-((2R,3S)-3-(methoxycarbonyl)-2-methylaziridin-2-yl)-1H-pyrazole-5-carboxylate **3s**: colorless oil, 97% yield, 99.9% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, *t* (major) = 8.02 min]; $[\alpha]_{\text{D}}^{25}$ = +237.5 (*c* = 0.347, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.82 (d, *J* = 7.4 Hz, 1H), 7.44 (d, *J* = 7.5 Hz, 1H), 7.38-7.27 (m, 3H), 4.51-4.32 (m, 2H), 3.89 (s, 3H), 3.22 (s, 1H), 2.05 (brs, 1H), 1.95 (s, 3H), 1.41 (t, *J* = 7.1 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 169.77, 158.83, 147.97, 133.20, 132.28, 131.04, 130.66, 130.22, 129.32, 126.85, 112.78, 61.34, 58.48, 52.89, 42.02, 18.57, 14.20. HRMS(ESI) *m/z* calcd for $\text{C}_{17}\text{H}_{19}\text{ClN}_3\text{O}_4$ ($[\text{M}+\text{H}]^+$): 364.1064, found: 364.1072.




Ethyl 3-(4-fluorophenyl)-1-((2R,3S)-3-(methoxycarbonyl)-2-methylaziridin-2-yl)-1H-pyrazole-5-carboxylate **3t**: colorless oil, 98% yield, 99.6% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, *t* (major) = 9.11 min, *t* (minor) = 18.54 min]; $[\alpha]_{\text{D}}^{25}$ = +208.2 (*c* = 0.341, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.89-7.73 (m, 2H), 7.18-7.00 (m, 3H), 4.49-4.32 (m, 2H), 3.90 (s, 3H), 3.19 (s, 1H), 2.04 (brs, 1H), 1.93 (s, 3H), 1.41 (t, *J* = 7.1 Hz, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 169.64, 162.85 (d, *J* = 245.3 Hz), 158.70, 149.50, 134.16, 128.41, 127.51 (d, *J* = 8.1 Hz), 115.49 (d, *J* = 21.5 Hz), 108.55, 61.28, 58.37, 52.74, 42.06, 18.53, 14.13. HRMS(ESI) *m/z* calcd for $\text{C}_{17}\text{H}_{19}\text{FN}_3\text{O}_4$ ($[\text{M}+\text{H}]^+$): 348.1360, found: 348.1349.




Ethyl 3-(2-fluorophenyl)-1-((2R,3S)-3-(methoxycarbonyl)-2-methylaziridin-2-yl)-1H-pyrazole-5-carboxylate **3u**: colorless oil, 97% yield, 99.9% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, *t* (major) = 7.91 min, *t* (minor) = 15.81 min]; $[\alpha]_{\text{D}}^{25}$ = +179.8 (*c* = 0.337, EtOAc). ^1H NMR (400 MHz,

CDCl₃) δ 8.05 (t, J = 7.6 Hz, 1H), 7.35-7.28 (m, 1H), 7.26-7.24 (m, 1H), 7.19 (t, J = 7.5 Hz, 1H), 7.17-7.09 (m, 1H), 4.46-4.35 (m, 2H), 3.90 (s, 3H), 3.21 (s, 1H), 2.10 (brs, 1H), 1.94 (s, 3H), 1.41 (t, J = 7.1 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 169.68, 160.11 (d, J = 248.4 Hz), 158.76, 144.95, 133.75, 129.55 (d, J = 8.3 Hz), 128.52 (d, J = 3.0 Hz), 124.14 (d, J = 3.2 Hz), 120.04 (d, J = 11.3 Hz), 115.89 (d, J = 22.0 Hz), 112.18 (d, J = 9.7 Hz), 61.21, 58.43, 52.69, 41.98, 18.50, 14.10. HRMS(ESI) m/z calcd for C₁₇H₁₉FN₃O₄ ([M+H]⁺): 348.1360, found: 348.1361.




Ethyl 1-((2R,3S)-3-(methoxycarbonyl)-2-methylaziridin-2-yl)-3-(p-tolyl)-1H-pyrazole-5-carboxylate **3v**: colorless oil, 98% yield, 99.9% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, t (major) = 7.48 min, t (minor) = 14.22 min]; [α]_D²⁵ = +203.8 (c = 0.320, EtOAc). ¹H NMR (400 MHz, CDCl₃) δ 7.93 (d, J = 8.2 Hz, 2H), 7.65 (d, J = 8.3 Hz, 2H), 7.16 (s, 1H), 4.55-4.32 (m, 2H), 3.91 (s, 3H), 3.20 (s, 1H), 2.06 (brs, 1H), 1.95 (s, 3H), 1.42 (t, J = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 169.86, 158.87, 150.49, 138.10, 133.85, 129.30, 125.67, 108.65, 61.26, 58.34, 52.88, 42.09, 21.24, 18.58, 14.20. HRMS(ESI) m/z calcd for C₁₈H₂₂N₃O₄ ([M+H]⁺): 344.1605, found: 344.1608.



Ethyl 1-((2R,3S)-3-(methoxycarbonyl)-2-methylaziridin-2-yl)-3-(4-(trifluoromethyl)phenyl)-1H-pyrazole-5-carboxylate **3w**: white solid, 72% yield, 99% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, t (major) = 7.15 min, t (minor) = 12.98 min]; m.p. 85.1-85.8 °C, [α]_D²⁵ = +306.6 (c = 0.286, EtOAc). ¹H NMR (400 MHz, CDCl₃) δ 7.93 (d, J = 8.0 Hz, 2H), 7.65 (d, J = 8.1 Hz, 2H), 7.16 (s, 1H), 4.52-4.29 (m, 2H), 3.91 (s, 3H), 3.20 (s, 1H), 2.06 (brs, 1H), 1.95 (s, 3H), 1.42 (t, J = 7.1 Hz, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 169.59, 158.58, 148.92, 135.62, 134.45, 130.10 (q, J = 32.1 Hz), 125.93, 125.54 (d, J = 3.8 Hz), 124.07 (q, J = 260.9 Hz), 109.09, 61.41, 58.56, 52.78, 42.03, 18.50, 14.11. HRMS(ESI) m/z calcd for C₁₈H₁₉F₃N₃O₄ ([M+H]⁺): 398.1328, found: 398.1330.


General procedure and characterization data for chiral arylpyrazole substituted aziridine (2S, 3R)-**3n**:

General procedure for chiral arylpyrazole substituted aziridine (2S, 3R)-**3n**:



A solution of 5-aryl-1H-pyrazole-3-carboxylic ester **1a** (0.12 mmol) and TsOH (20 mol %, 0.02 mmol) in 1.0 mL cyclohexane was stirred at 25 °C for 10 min, then chiral 2H-azirine carboxylic ester (*R*)-**2n** (0.1 mmol) was added. The reaction mixture was stirred at 25 °C until the reaction was completed. After removal of the solvent, the residue was purified by flash column chromatography to afford the pure product.

Characterization data for chiral arylpyrazole substituted aziridine (2S, 3R)-**3n**:



Ethyl 3-(4-bromophenyl)-1-((2S,3R)-3-(methoxycarbonyl)-2-(4-(trifluoromethyl)phenyl)aziridin-2-yl)-1H-pyrazole-5-carboxylate (2S, 3R)-**3n**: white solid, 79% yield, 98% ee [Daicel Chiralcel AS-H column, *n*-hexane / *i*-PrOH = 90 : 10, 1.0 ml/min, λ = 254 nm, *t* (minor) = 9.12 min, *t* (major) = 14.53 min]; m.p. 138.3-139.2 °C, $[\alpha]_D^{25}$ = -532.3 (*c* = 0.426, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.75 (d, *J* = 7.8 Hz, 2H), 7.69 (d, *J* = 7.4 Hz, 2H), 7.56 (d, *J* = 7.7 Hz, 4H), 7.11 (s, 1H), 4.31 (q, *J* = 6.4 Hz, 2H), 3.84 (s, 1H), 3.65 (s, 3H), 3.00 (brs, 1H), 1.34 (t, *J* = 6.8 Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3) δ 167.73, 158.22, 149.78, 137.65, 135.03, 131.79, 130.87, 130.82 (q, *J* = 32.3 Hz), 128.25, 127.35, 125.12, 124.87 (d, *J* = 3.5 Hz), 123.78 (q, *J* = 271.1 Hz), 109.45, 61.37, 52.64, 43.80, 14.04. HRMS(ESI) *m/z* calcd for $\text{C}_{23}\text{H}_{20}\text{BrF}_3\text{N}_3\text{O}_4$ ($[\text{M}+\text{H}]^+$): 538.0584, found: 538.0581.


General procedure and characterization data for H_8 -BINOL derived chiral imidodiphosphoric acids **4**:

H_8 -BINOL derived chiral imidodiphosphoric acids **4a-4e** were synthesized according to our previous work.³ Catalyst **4e** were first synthesized in this work and the characterization data was given.

General procedure for H_8 -BINOL derived chiral imidodiphosphoric acids **4e**:

NaH (60% in oil, 3 mmol) was added to a stirred solution of 9-anthracenyl substituted H_8 -BINOL-type phosphoryl chloride (1.2 mmol) in dry DMF (10 ml) under nitrogen atmosphere at room temperature. After stirring for 5 min, 1-naphthyl substituted H_8 -BINOL-type phosphoramidate (1 mmol) was added and the mixture was stirred for another 1 h. After the reaction was completed, 30 ml CH_2Cl_2 was added to the flask and the mixture was washed with saturated brine (50 ml $\times$ 5). The organic layer was dried over Na_2SO_4 and concentrated under reduced pressure. The crude product was purified with silica gel column chromatography. Then the product was dissolved in CH_2Cl_2 , acidified with 3 M HCl (10 ml), washed with brine (30 ml $\times$ 5), dried over Na_2SO_4 and concentrated in vacuo. The product was further purified by recrystallization in THF and methanol to give catalyst **4e**.


Characterization data for H_8 -BINOL derived chiral imidodiphosphoric acids **4e**:



H_8 -BINOL derived chiral imidodiphosphoric acids **4e**: white solid, 52% yield, ^1H NMR (300 MHz, CDCl_3) δ 8.19 (s, 2H), 8.06 (d, *J* = 6.4 Hz, 1H), 7.94-7.85 (m, 1H), 7.77 (t, *J* = 6.4 Hz, 1H), 7.69-7.45 (m, 12H), 7.38-7.34 (m, 3H), 7.30-7.16 (m, 3H), 7.04-6.76 (m, 4H), 6.68 (t, *J* = 7.2 Hz, 1H), 6.60-6.50 (m, 4H), 6.32 (s, 1H), 6.20-5.92 (m, 3H), 5.69-5.60 (m, 1H), 2.99-2.28 (m, 16H), 2.12-1.75 (m, 16H). ^{13}C NMR (75 MHz, CDCl_3) δ 145.59, 145.32, 145.00, 143.75, 138.01, 137.21, 136.75, 135.05, 134.83, 134.62, 133.71, 133.48, 133.20, 132.99, 132.65, 132.38, 132.06, 131.80, 130.85, 130.67, 130.42, 130.20, 129.71, 128.40, 128.11, 127.82, 127.32, 127.19, 126.84, 126.45, 126.19, 125.86, 125.27, 124.76, 124.50, 124.11, 123.97, 123.28, 29.64, 29.51, 29.42, 29.13, 28.98, 28.89, 28.47, 28.13, 27.95, 27.71, 23.17, 23.08, 22.85, 22.80, 22.77, 22.64, 22.52. ^{31}P NMR (162 MHz, CDCl_3) δ 6.73, 6.31, 5.41, 4.99. HRMS(ESI) *m/z* calcd for $\text{C}_{88}\text{H}_{70}\text{NO}_6\text{P}_2$ ($[\text{M}+\text{H}]^+$): 1298.4678, found: 1298.4686.


General procedure and characterization data for chiral arylpyrazole substituted aziridines **6**:

General procedure for chiral arylpyrazole substituted aziridines **6**:



A solution of 5-aryl-1H-pyrazole-3-carboxylic esters **1a** (0.1 mmol) and catalyst **4e** (10 mol %, 0.01 mmol) in 1.0 mL cyclohexane was stirred at 25 °C for 10 min, then 3-phenyl-2H-azirine **5** (0.12 mmol) was added. The reaction mixture was stirred at 25 °C for 6 d. After removal of the solvent, the residue was purified by flash column chromatography to afford the pure products.


Characterization data for chiral arylpyrazole substituted aziridines **6**:



Ethyl 3-(4-bromophenyl)-1-(2-phenylaziridin-2-yl)-1H-pyrazole-5-carboxylate **6**: colorless oil, 62% yield, 77% ee [Daicel Chiralcel OD-H column, *n*-hexane / *i*-PrOH = 95 : 5, 1.0 ml/min, λ = 254 nm, *t* (minor) = 15.14 min, *t* (major) = 18.76 min]; $[\alpha]_D^{25} = +144.7$ (*c* = 0.253, EtOAc). ^1H NMR (400 MHz, CDCl_3) δ 7.75 (d, *J* = 7.6 Hz, 2H), 7.55 (d, *J* = 7.3 Hz, 2H), 7.37-7.26 (m, 3H), 7.20 (s, 1H), 7.12 (d, *J* = 7.1 Hz, 2H), 4.26 (q, *J* = 6.5 Hz, 2H), 2.87 (s, 1H), 2.65 (s, 1H), 1.62 (brs, 1H), 1.27 (t, *J* = 6.4 Hz, 3H). ^{13}C NMR (101 MHz, DMSO) δ 158.44, 148.81, 140.39, 136.21, 132.21, 131.66, 128.70, 127.99, 127.76, 125.09, 121.95, 109.33, 61.36, 14.30. HRMS(ESI) *m/z* calcd for $\text{C}_{20}\text{H}_{19}\text{BrN}_3\text{O}_2$ ($[\text{M}+\text{H}]^+$): 412.0661, found: 412.0652.

X-Ray Structures of **3e**:


Good quality crystal of **3e** was obtained by recrystallization in ethanol. CCDC 1486543 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.






- (1) (a) Çalışkan, B.; Yılmaz, A.; Evren, İ.; Menevşe, S.; Uludag, O.; Banoglu, E. *Med. Chem. Res.* **2012**, *22*, 782. (b) Kamal, A.; Shaik, A. B.; Polepalli, S.; Reddy, V. S.; Kumar, G. B.; Gupta, S.; Krishna, K. V.; Nagabhushana, A.; Mishra, R. K.; Jain, N. *Org. Biomol. Chem.* **2014**, *12*, 7993. (c) Nagarapu, L.; Mateti, J.; Gaikwad, H. K.; Bantu, R.; Sheeba Rani, M.; Prameela Subhashini, N. J. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 4138.
- (2) (a) Wang, Y.; Lei, X.; Tang, Y. *Chem. Commun.* **2015**, *51*, 4507. (b) Ryu, T.; Baek, Y.; Lee, P. H. *J. Org. Chem.* **2015**, *80*, 2376. (c) Loy, N. S. Y.; Kim, S.; Park, C. M. *Org. Lett.* **2015**, *17*, 395. (d) Loy, N. S. Y.; Singh, A.; Xu, X.; Park, C. M. *Angew. Chem.* **2013**, *125*, 2268.
- (3) Fan, Y.-S.; Jiang, Y.-J.; An, D.; Sha, D.; Antilla, J. C.; Zhang, S. *Org. Lett.* **2014**, *16*, 6112.

NMR spectra:




2a:






2b:






2c:






2d:






2e:






2f:




2g:






2h:






2i:






2k:





2l:






2n:






3a:






3b:






3c:






3d:






3e:






3f:






3g:






3h:






3i:






3j:






3k:






3l:






3m:






3n:




30:






3p:






3q:






3r:






3s:




3t:






3u:




3v:





3w:






4e:







6:




HPLC spectra of racemic and enantioenriched products:

2a:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	8.50333	271.59	54.04282	5839.07	50.0657
2	12.37917	230.95	45.95718	5823.74	49.9343




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	8.54583	0.17	1.08655	4.14	0.9266
2	12.77083	15.41	98.91345	442.82	99.0734

2b:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	12.54000	17.62	55.27070	574.67	48.8665
2	18.34500	14.26	44.72930	601.33	51.1335




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	12.38665	0.15	1.38392	3.04	0.6345
2	18.22917	10.86	98.61608	476.24	99.3655

2c:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	8.50333	88.18	51.98659	3154.66	49.4276
2	10.68167	81.44	48.01341	3227.73	50.5724




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	8.51254	0.39	1.27614	5.81	0.4766
2	10.73833	30.31	98.72386	1213.80	99.5234

2d:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	15.94917	51.04	58.80747	1679.73	49.9390
2	26.32333	35.75	41.19253	1683.84	50.0610




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	15.92354	0.16	0.75336	4.98	0.5035
2	25.95750	21.67	99.24664	983.43	99.4965

2e:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	9.30583	129.85	61.34985	4176.49	50.6608
2	19.69667	81.81	38.65015	4067.53	49.3392




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	9.42833	0.58	2.53855	13.33	1.3582
2	20.26500	22.09	97.46145	967.98	98.6418

2g:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	6.72500	161.76	55.34529	3545.74	49.6431
2	10.61083	130.51	44.65471	3596.73	50.3569




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	6.28500	0.23	0.55490	6.03	0.5418
2	9.75417	40.36	99.44510	1107.22	99.4582

2i:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	18.59167	129.18	52.78138	8936.56	50.1498
2	28.88667	115.57	47.21862	8883.17	49.8502




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	16.39917	13.99	4.34273	443.58	3.0337
2	24.26500	308.21	95.65727	14178.15	96.9663

2k:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	10.484	638.436	56.2	16068.870	49.6562
2	16.977	496.953	43.8	16291.368	50.3438




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	10.272	11.856	2.6	270.250	1.5708
2	15.902	448.647	97.4	16934.868	98.4292

2l:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	9.504	433.082	55.6	10559.807	50.1620
2	14.894	346.090	44.4	10491.595	49.8380




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	9.316	9.980	3.1	216.453	2.1718
2	14.100	307.047	96.9	9750.201	97.8282

2n:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	9.811	388.482	50.1	16301.858	50.3592
2	18.087	387.509	49.9	16069.279	49.6408




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	9.492	1.055	1.1	40.952	1.0676
2	17.240	98.457	98.9	3795.001	98.9324

3a:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	7.739	146.395	68.5	6467.712	50.9820
2	15.823	67.211	31.5	6218.546	49.0180




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	7.734	687.979	100.0	29925.474	99.9625
2	15.770	0.188	0.0	11.221	0.0375

3b:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	8.661	91.854	68.8	3793.823	49.3700
2	16.309	41.745	31.2	3890.643	50.6300




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	9.196	353.210	100.0	18285.441	99.9450
2	18.715	0.161	0.0	10.055	0.0550

3c:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	7.521	90.745	53.4	6924.902	50.0414
2	14.613	79.164	46.6	6913.450	49.9586




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	7.835	422.273	100.0	31608.543	99.9820
2	14.958	0.004	0.0	5.687	0.0180

3d:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	12.473	85.018	51.2	9869.518	52.5921
2	24.168	80.979	48.8	8896.633	47.4079




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	13.128	230.794	100.0	30472.473	99.9830
2	26.153	0.010	0.0	5.174	0.0170

3e:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	6.540	245.709	77.3	10070.872	49.5698
2	18.801	71.997	22.7	10245.657	50.4302




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	6.553	356.456	100.0	15064.703	99.9514
2	18.877	0.149	0.0	7.324	0.0486

3f:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	5.447	628.695	69.9	25575.661	50.1330
2	12.441	270.294	30.1	25439.955	49.8670




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	5.414	382.084	99.9	14621.391	99.7845
2	12.313	0.509	0.1	31.582	0.2155

3g:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	4.990	143.086	66.6	6040.164	48.7919
2	10.953	71.733	33.4	6339.281	51.2081




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	4.993	179.666	100.0	7660.563	99.9816
2	9.882	0.061	0.0	1.413	0.0184

3h:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	5.399	229.103	70.1	6685.291	48.5864
2	11.140	97.600	29.9	7074.308	51.4136




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	5.381	227.417	99.8	6673.644	99.6379
2	11.068	0.476	0.2	24.252	0.3621

3i:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	8.457	38.106	72.9	1667.094	48.5885
2	21.975	14.175	27.1	1763.954	51.4115




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	8.346	392.499	99.4	18033.560	98.5635
2	21.402	2.482	0.6	262.821	1.4365

3j:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	13.802	63.602	64.2	4845.514	50.9073
2	21.869	35.438	35.8	4672.788	49.0927




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	13.763	115.128	99.3	8852.730	99.0086
2	21.661	0.760	0.7	88.649	0.9914

3k:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	13.576	33.537	65.0	2931.443	50.2462
2	23.250	18.049	35.0	2902.710	49.7538




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	13.053	301.677	99.9	26432.245	99.8408
2	22.370	0.376	0.1	42.136	0.1592

3l:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	6.039	171.792	74.0	3985.619	49.9795
2	13.308	60.314	26.0	3988.888	50.0205




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	7.589	840.004	100.0	25126.172	99.9590
2	12.916	0.191	0.0	10.305	0.0410

3m:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	19.146	43.904	66.6	4812.438	52.1712
2	33.288	22.029	33.4	4411.882	47.8288




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	17.583	80.989	99.9	7973.814	99.7685
2	29.890	0.094	0.1	18.499	0.2315

3n:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	8.689	135.892	65.1	7316.537	49.6600
2	13.726	72.863	34.9	7416.720	50.3400




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	8.681	774.137	100.0	42260.187	99.9753
2	13.256	0.003	0.0	10.434	0.0247

(-)-3n:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	8.689	135.892	65.1	7316.537	49.6600
2	13.726	72.863	34.9	7416.720	50.3400




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	9.116	1.848	1.5	98.934	0.6724
2	14.532	122.168	98.5	14614.466	99.3276

30:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	18.348	131.676	75.8	9333.174	49.1371
2	38.657	42.138	24.2	9660.976	50.8629




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	18.370	103.643	99.8	7697.860	99.5641
2	39.180	0.240	0.2	33.699	0.4359

3p:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	11.789	93.479	68.2	6769.246	50.0547
2	25.347	43.681	31.8	6754.457	49.9453




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	11.928	380.676	100.0	31723.309	99.9771
2	27.150	0.096	0.0	7.266	0.0229

3q:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	6.945	327.465	69.3	11892.252	50.9722
2	11.163	145.044	30.7	11438.607	49.0278




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	6.633	685.697	100.0	24765.362	99.9952
2	10.251	0.001	0.0	1.179	0.0048

3r:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	8.054	142.924	53.1	8247.937	49.3048
2	14.177	126.186	46.9	8480.517	50.6952




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	7.869	321.436	100.0	18499.239	99.9615
2	16.205	0.153	0.0	7.132	0.0385

3s:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	8.075	92.038	40.4	7004.399	48.1779
2	13.605	135.993	59.6	7534.228	51.8221




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	8.015	326.410	100.0	24100.117	100.0000

3t:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	9.111	173.826	73.7	6319.381	50.1590
2	18.550	61.871	26.3	6279.320	49.8410




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	9.111	248.581	99.9	9162.784	99.8188
2	18.540	0.211	0.1	16.633	0.1812

3u:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	7.720	84.364	54.7	3745.538	49.2495
2	14.386	69.891	45.3	3859.698	50.7505




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	7.911	187.612	100.0	9016.181	99.9771
2	15.812	0.054	0.0	2.068	0.0229

3v:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	7.748	188.311	67.5	8428.868	50.7236
2	15.435	90.625	32.5	8188.373	49.2764




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	7.484	272.667	100.0	12191.731	99.9818
2	14.217	0.041	0.0	2.221	0.0182

3w:





Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	7.301	83.549	66.3	3871.573	50.8486
2	13.209	42.406	33.7	3742.355	49.1514




Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	7.150	127.776	99.7	6214.459	99.5590
2	12.975	0.382	0.3	27.530	0.4410

6:



Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	14.610	349.861	49.5	16051.429	49.4209
2	17.869	357.322	50.5	16427.582	50.5791



Peak	RT [min]	Height [mV]	Height %	Area[mV*s]	Area%
1	15.136	19.967	11.1	961.549	11.5226
2	18.757	159.726	88.9	7383.365	88.4774